Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma
Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate…
Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Therapies for Diabetes
Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Diabetes Therapies Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop…
Lilly’s Mirvetuximab Soravtansine Earns FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer
Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation…
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001 Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company,…
Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases
Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic…
Bristol Myers Squibb Partners with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection
Bristol Myers Squibb Teams Up with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection Bristol Myers Squibb, a global leader in oncology, today announced an agreement with Microsoft, a market…
Moderna & Merck: 5-Year Data Show Sustained RFS Benefit with Intismeran + KEYTRUDA® in High-Risk Melanoma
Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck…
ENHERTU® + Pertuzumab Validated in EU for First-Line HER2+ Metastatic Breast Cancer
ENHERTU® Plus Pertuzumab Moves Closer to EU Approval as First-Line Therapy for HER2-Positive Metastatic Breast Cancer In a significant milestone for oncology innovation, the European Medicines Agency (EMA) has officially…
Bioscience Association Manitoba Joins Premier’s Workforce Development Subcommittee
Bioscience Association Manitoba Joins Premier’s Workforce Development Subcommittee to Shape the Future of Talent and Economic Growth In a significant step toward aligning Manitoba’s economic strategy with the demands of…
Shionogi Wins Health Minister Award for Cefiderocol at Japan AMED Grand Prize
Shionogi Receives Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief…
Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation
Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to…
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in R/R DLBCL
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in Relapsed/Refractory DLBCL AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific…